On Thursday, the EU’s drug watchdog approved two Covid-19 antibody treatments, in its first approvals of the groundbreaking therapies that help stop infected people from developing symptoms of the disease.
Ronapreve, made by Swiss pharma giant Roche with US biotech firm Regeneron, and Regkirona, developed by South Korea’s Celltrion, got the green light from the European Medicines Agency (EMA). The move adds to the European Union’s toolbox of drugs as it fights coronavirus infection rates that are rising to record levels in some countries.
Ronapreve and Regkirona are the first monoclonal antibody medicines to receive a positive opinion for Covid-19. Lab-produced monoclonal antibodies are Y-shaped proteins that bind to the spikes that dot the surface of the coronavirus, stopping the pathogen from invading human cells.